1. Introduction {#sec1-ijerph-16-03147}
===============

Most patients exposed to organophosphates came into contact with insecticides. Some examples of organophosphate pesticides are malathion, parathion, and diazinon. Other examples of organophosphate anticholinesterases include the chemical weapon sarin and VX nerve agent (venomous agent X). Organophosphates are potent cholinesterase inhibitors capable of causing severe cholinergic toxicity following cutaneous exposure, inhalation, or ingestion. Organophosphates provoke the irreversible inhibition of acetylcholinesterase, leading to acetylcholine accumulation in muscarinic and nicotinic cholinergic synapses in the nervous system. The clinical features of organophosphate poisoning include increased saliva and tear production, diarrhea, nausea, vomiting, small pupils, sweating, muscle tremors, and confusion \[[@B1-ijerph-16-03147]\]. Approximately 10 to 40% of patients with organophosphate poisoning develop neurological disorders 1 to 4 days after exposure. The neurological symptoms include neck flexion weakness, decreased deep tendon reflexes, cranial nerve abnormalities, proximal muscle weakness, and respiratory insufficiency \[[@B2-ijerph-16-03147]\].

Clinically, respiratory failure is the main cause of death in severe organophosphate poisoning. Respiratory failure is attributed to a combination of bronchoconstriction, respiratory muscle paralysis, and damage to the medullary respiratory centers \[[@B3-ijerph-16-03147]\]. The effects of organophosphates on the central nervous system include irritability, restlessness, disorientation, and confusion, which can evolve into generalized seizures, status epilepticus, and brain damage \[[@B4-ijerph-16-03147]\]. Status epilepticus following organophosphate exposure can last 30 min or longer, causing profound brain damage resulting in neuronal damage or death \[[@B5-ijerph-16-03147],[@B6-ijerph-16-03147],[@B7-ijerph-16-03147]\]. The effects of organophosphate intoxication are long-lasting, and survivors experience chronic brain damage and face the risk of neurological and cognitive deficits \[[@B8-ijerph-16-03147],[@B9-ijerph-16-03147]\]. Status epilepticus and chronic brain damage following organophosphate exposure can contribute to epileptogenesis \[[@B10-ijerph-16-03147],[@B11-ijerph-16-03147]\]. However, no study has evaluated the rate of seizure disorder development after organophosphate poisoning using long-term follow-ups.

We used representative Taiwan National Health Insurance (NHI) data sets to form a cohort and examine whether individuals face an increased risk of seizures years after organophosphate poisoning. To date, this is the largest cohort used to investigate this topic.

2. Methods {#sec2-ijerph-16-03147}
==========

2.1. Data Source {#sec2dot1-ijerph-16-03147}
----------------

The present study was conducted using the Taiwan National Health Insurance Research Database (NHIRD). The NHI program was implemented in Taiwan on 1 March 1995. This program covers over 99% of the 23.74 million Taiwanese residents (<http://www.nhi.gov.tw/english/index.aspx>). In 1999, as part of the NHIRD project, the Bureau of NHI began to release patient data in an electronic format for research purposes. These de-identified secondary data include all registry and claims data. In this study, we used the hospitalization claims data of all enrollees in Taiwan, including sex, birth date, dates of admission and discharge, diagnoses, operations, discharge statuses, and expenditures by admission. The diagnostic codes are based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Because the data set consists of de-identified secondary data, the study was exempted from full review by the Institutional Research Ethics Committee (CMUH104-REC2-115-CR4).

2.2. Sample Cohort {#sec2dot2-ijerph-16-03147}
------------------

The study cohorts were identified from inpatient claims between 1 January 2000 and 31 December 2011; individuals diagnosed with organophosphate poisoning (ICD-CM-9 code 989.3) were considered the organophosphate poisoning cohort. The date of the first admission for organophosphate poisoning was used as the index date. We excluded patients with epilepsy (ICD-9-CM code 345) before the index date, aged less than 20 years, or with incomplete information. For each patient with organophosphate poisoning, we randomly selected four controls without the condition from among the NHI beneficiaries and used the same exclusion criteria. The controls were frequency-matched with the organophosphate poisoning cohort by age (five-year groups) and sex.

2.3. Outcome {#sec2dot3-ijerph-16-03147}
------------

We identified diagnoses of epilepsy in hospitalization records from 2000 to 2011 as the study endpoint. All of the study individuals were followed up from the index date to the endpoint, withdrawal from the NHI, or the end of 2011, whichever came first.

2.4. Comorbidities {#sec2dot4-ijerph-16-03147}
------------------

A history of diabetes (ICD-9-CM code 250), hypertension (ICD-9-CM code 401--405), hyperlipidemia (ICD-9-CM code 272), head injury (ICD-9-CM codes 310.2, 800, 801, 803, 804, 850, 851, 853, 854), depression (ICD-9-CM codes 296.2, 296.3, 296.82, 300.4, 311), stroke (ICD-9-CM code 430--438), cirrhosis (ICD-9-CM code 571), coronary artery disease (CAD) (ICD-9-CM codes 410--414), congestive heart failure (CHF) (ICD-9-CM code 428), or atrial fibrillation (AF) (ICD-9-CM code 427.31) identified at baseline from the patients' hospitalization records was considered a comorbidity.

2.5. Statistical Analysis {#sec2dot5-ijerph-16-03147}
-------------------------

The distributions of baseline characteristics (age, sex, and comorbidities) of the organophosphate poisoning and control cohorts were compared using the chi-square test. We used the Student's t-test for continuous variables. We assessed the cumulative incidence of epilepsy using the Kaplan-Meier method between the organophosphate poisoning and control cohorts. Their differences were estimated using a log-rank test. The incidence density rates (per 10,000 person years) by sex, age, and comorbidity were calculated for both cohorts. The relative hazard ratio (HR) of developing epilepsy in patients with organophosphate poisoning compared with patients without organophosphate poisoning was analyzed through univariable and multivariable Cox proportion hazard regressions. The multivariable model was adjusted for age, sex, and comorbidities of diabetes, hypertension, hyperlipidemia, head injury, depression, stroke, cirrhosis, CAD, CHF, and AF, simultaneously. Only confounding variables deemed significant in the multivariable model were further analyzed. Further analysis was performed to assess whether the association of epilepsy varied according to the length of the follow-up period after organophosphate poisoning was diagnosed. All analyses were conducted using the SAS statistical software package (Version 9.2 for Windows; SAS Institute, Inc., Cary, NC, USA). All statistical tests were performed considering a two-tailed significance level of 0.05.

3. Results {#sec3-ijerph-16-03147}
==========

The distributions of the demographic variables and comorbidities for the organophosphate poisoning and control cohorts are presented in [Table 1](#ijerph-16-03147-t001){ref-type="table"}. The mean (±standard deviation (SD)) age of the organophosphate poisoning cohort was 53.3 (±16.1) years and that of the controls was 53.2 (±16.3) years, with 43.3% aged 20--49 years. Female patients were outnumbered by male patients. The organophosphate poisoning cohort was more likely to experience comorbidities than the control cohort (all *p*-values \< 0.001). The mean follow-up times for the organophosphate poisoning and control cohorts were 5.50 (SD = 3.83) and 6.57 (SD = 3.42) years, respectively (data not presented). As illustrated by [Figure 1](#ijerph-16-03147-f001){ref-type="fig"}, the cumulative incidence of seizures estimated through the Kaplan-Meier analysis was 1.63% higher in the organophosphate poisoning cohort than in the control cohort over the follow-up period (*p* \< 0.001).

The overall incidence of epilepsy was 3.62-fold higher in the organophosphate poisoning cohort than in the control cohort (23.8 vs. 5.13 per 10,000 person years), with an adjusted HR of 3.57 (95% confidence interval (CI) = 2.73--4.68) during the 12 year follow-up period ([Table 2](#ijerph-16-03147-t002){ref-type="table"}). The gender-specific analysis revealed that the risk of epilepsy of the organophosphate poisoning cohort compared with that of the control cohort was significantly higher for both female (adjusted HR = 3.55, 95% CI = 1.93--6.52) and male patients (adjusted HR = 3.47, 95% CI = 2.56--4.69). The age-specific adjusted HR was highest in the patients with organophosphate poisoning aged 20--34 years (adjusted HR = 13.0, 95% CI = 5.40--31.4), followed by that of poisoning patients aged 35--49 years (adjusted HR = 5.61, 95% CI = 2.94--10.7), 50--64 years (adjusted HR = 2.19, 95% CI = 1.27--3.77), and 65 or older (adjusted HR = 2.48, 95% CI = 1.59--3.87). The comorbidity-specific analysis revealed that the incidence of epilepsy was higher in both cohorts among patients with comorbidities.

[Table 3](#ijerph-16-03147-t003){ref-type="table"} depicts the interaction of organophosphate poisoning and comorbidities and its effect on the risk of epilepsy. Patients with organophosphate poisoning and stroke were at a much higher risk of seizures (adjusted HR = 15.1, 95% CI = 9.35--24.4) compared with patients with stroke alone (HR = 7.19, 95% CI = 4.58--11.3) or organophosphate poisoning alone (HR = 5.04, 95% CI = 3.80--6.68) (*p*-value of interaction = 0.004).

In addition, the interactions of organophosphate poisoning with hypertension interaction, head injury, CHF, and AF had significant effects on epilepsy risk (all interaction *p*-values \< 0.05). When compared with individuals without organophosphate poisoning or cirrhosis, the adjusted HR increased to 16.6 (95% CI = 10.8--25.6) for patients with both organophosphate poisoning and cirrhosis. The risk decreased over time but persisted throughout the follow-up period ([Table 4](#ijerph-16-03147-t004){ref-type="table"}). The highest risk occurred during the first year of the follow-up period (adjusted HR = 7.71, 95% CI = 4.23--14.0) and decreased with time to 3.71 at 2--5 years of follow-up. The risk remained for more than 5 years of follow-up.

4. Discussion {#sec4-ijerph-16-03147}
=============

To the best of our knowledge, this is the first report on the prevalence of seizure disorder in long-term outcomes after organophosphate poisoning. Compared with the control cohort, patients with organophosphate poisoning had a 3.57-fold higher seizure incidence (95% CI = 2.73--4.68). The patients with organophosphate poisoning with a history of stroke had a much higher risk of seizures than patients with stroke or organophosphate poisoning alone. The risk of seizures was highest during the first year of follow-up and decreased over the follow-up period, but remained significantly higher in the poisoning cohort after 5 years of follow-up.

The primary cause of death induced by organophosphate poisoning is respiratory paralysis; other major toxic signs include electrographic seizures in the brain and consequent motor convulsions. These seizures can rapidly progress to status epilepticus and can contribute to chronic brain damage \[[@B10-ijerph-16-03147]\]. Chronic brain damage can lead to the process of epileptogenesis \[[@B11-ijerph-16-03147]\]. Based on the available data for pesticides, seizures are more common in young patients. The incidence of tonic--clonic seizures averaged 25% in young patients, compared with 2.5% in adults \[[@B12-ijerph-16-03147]\]. Similar findings were observed in the present study. The risk of seizure disorder after organophosphate intoxication was higher in patients under 50 years of age. Previous reports have demonstrated that in young people, the predominant signs and symptoms associated with the central nervous system are common \[[@B12-ijerph-16-03147],[@B13-ijerph-16-03147]\]. The incidence of tonic--clonic seizures is approximately 10-fold higher in young patients than in adults \[[@B14-ijerph-16-03147]\]. These age-related differences in the susceptibility to seizures can be attributed to differences in the dose to body weight ratio, metabolizing enzymes, permeability of membranes, and distribution of fat \[[@B12-ijerph-16-03147]\].

After any brain injury, subsequent seizures can occur due to the hyperexcitable electrical activity of the cerebral cortex after cell damage \[[@B15-ijerph-16-03147]\]. For example, patients with severe strokes or hemorrhagic strokes are at a higher risk of epileptic seizures. Galovic et al. developed a multivariate model evaluating the risk of late seizures within 5 years after a stroke \[[@B16-ijerph-16-03147]\]. Late seizures occurred in 4% of people during the first year after a stroke and in 8% within 5 years after a stroke. Roivainen et al. reported that patients from Finland aged 15--49 years had a 6.1% risk of late seizures in the first year and 9.5% within 5 years \[[@B17-ijerph-16-03147]\]. The first late seizure appeared more frequently within 1 year after a brain injury. Similar findings were observed in the present study of seizures in patients with organophosphate poisoning. The risk was highest during the first year, and the cumulative incidence of seizures remained elevated in the following years. Patients surviving organophosphate poisoning require a closer follow-up during the first year.

This study explored the risk of late-onset seizures after organophosphate poisoning. A higher percentage of seizures was observed in patients with comorbidities, for example in patients with a history of hypertension, stroke, head injury, CHF, or AF. A prospective, longitudinal, community-based cohort study examined the incidence and risk factors of seizures after an ischemic cerebral event (Framingham Heart Study) \[[@B18-ijerph-16-03147]\]. The study revealed that seizures occurred in 5.3% of participants after an ischemic cerebral event, and seizure incidence was 6.2% after cardioembolic events. AF and CHF are common conditions that predispose each other, share risk factors, and are associated with morbidity and mortality \[[@B19-ijerph-16-03147]\]. Irregular heartbeat and reduced cardiac output lead to reduced cerebral blood flow and potential brain damage \[[@B20-ijerph-16-03147],[@B21-ijerph-16-03147],[@B22-ijerph-16-03147]\]. Previous reports have indicated a relationship between AF and other neurological complications, such as seizure disorders \[[@B23-ijerph-16-03147],[@B24-ijerph-16-03147]\]. This may suggest that the underlying risk factors and causes of brain lesions continue to expose patients to new seizure events.

5. Limitations {#sec5-ijerph-16-03147}
==============

This study has several limitations. Firstly, because of its data-based study design, we were unable to control possible confounders (e.g., organophosphate poisoning severity, family history, medication, personal history), but the related comorbidities were measured reliably.

The second limitation of this study is that the severity and frequency of seizures could not be measured, and the seizure type could not be definitely classified in the analysis. Because electroencephalogram reports were not included in the data, patients with nonconvulsive seizures after organophosphate poisoning might have been underdiagnosed.

The third limitation of this study is that the diagnoses were provided by the treating physicians. The temporal relation between the onset of organophosphate exposure and seizures was based on the first appearance in the records. Therefore, the onset of the first seizure and the accurate diagnosis of epilepsy might have been considerably delayed.

The fourth limitation of this study is that the evidence derived from a retrospective record-based study is generally lower in statistical quality than that obtained from randomized trials. Despite a large-scale registry, meticulous study design, and the measures adopted to control confounding factors, bias resulting from unknown confounders may have affected our results.

Finally, patients with a history of comorbidities such as stroke, head injury, or atrial fibrillation have a higher risk of seizures. These comorbidities might influence the percentage of epilepsy in patients with organophosphate poisoning. Despite careful adjustment of related comorbidities, unknown confounders may have affected our results.

6. Conclusions {#sec6-ijerph-16-03147}
==============

This population-based retrospective cohort study demonstrated that patients with a history of organophosphate poisoning have an increased long-term risk of seizures; furthermore, organophosphate poisoning may be an independent risk factor for seizures. These findings yield the following clinical implication: physicians should consider the history of exposure to organophosphates when making a new diagnosis of seizure, especially in young adults. Future mechanistic investigations of organophosphate exposure and the risk of PD are warranted.
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###### 

Characteristics of patients with and without organophosphate poisoning.

  Variable                         Organophosphate Poisoning   *p*-Value                     
  -------------------------------- --------------------------- ----------- -------- -------- ---------
  Age, years                                                                                 0.99
  20--34                           1331                        (15.0)      5387     (14.5)   
  35--49                           2509                        (28.3)      10,268   (27.7)   
  50--64                           2651                        (29.9)      11,136   (30.0)   
  ≥65                              2374                        (26.8)      10,312   (27.8)   
  Mean (SD) \#                     53.3                        16.1        53.2     16.3     0.84
  Gender                                                                                     0.63
  Female                           2699                        (30.5)      11,200   (30.2)   
  Male                             6166                        (69.6)      25,903   (69.8)   
  Comorbidity                                                                                
  Diabetes                         1170                        (13.2)      1860     (5.01)   \<0.001
  Hypertension                     1836                        (20.7)      3112     (8.39)   \<0.001
  Hyperlipidemia                   512                         (5.78)      846      (2.28)   \<0.001
  Head injury                      928                         (10.5)      1060     (2.86)   \<0.001
  Depression                       1477                        (16.7)      158      (0.43)   \<0.001
  Stroke                           717                         (8.09)      1383     (3.73)   \<0.001
  Cirrhosis                        755                         (8.52)      892      (2.40)   \<0.001
  Coronary artery disease (CAD)    679                         (7.66)      1456     (3.92)   \<0.001
  Congestive heart failure (CHF)   220                         (2.48)      362      (0.98)   \<0.001
  Atrial fibrillation (AF)         120                         (1.35)      275      (0.74)   \<0.001

Chi-square test; \#: Student's t-test; SD denotes standard deviation.

ijerph-16-03147-t002_Table 2

###### 

Incidence and hazard ratio of seizures for patients with and without organophosphate poisoning.

  Variable          Organophosphate Poisoning                                                                     
  ----------------- --------------------------- -------- ------ ----- --------- ------ -------------------------- --------------------------
  All               116                         48,758   23.8   125   243,785   5.13   4.62 (3.59, 5.95) \*\*\*   3.57 (2.73, 4.68) \*\*\*
  Gender                                                                                                          
  Female            26                          14,721   17.8   26    74,471    3.49   5.00 (2.90, 8.61) \*\*\*   3.55 (1.93, 6.52) \*\*\*
  Male              90                          34,037   26.4   99    169,314   5.85   4.51 (3.39, 6.01) \*\*\*   3.47 (2.56, 4.69) \*\*\*
  Age, years                                                                                                      
  20--34            24                          8616     27.9   7     38,481    1.82   15.3 (6.57, 35.4) \*\*\*   13.0 (5.40, 31.4) \*\*\*
  35--49            35                          15,202   23.0   17    72,873    2.33   9.81 (5.50, 17.5) \*\*\*   5.61 (2.94, 10.7) \*\*\*
  50--64            25                          15,086   16.6   40    75,536    5.30   3.13 (1.90, 5.16) \*\*\*   2.19 (1.27, 3.77) \*\*
  ≥65               32                          9853     32.5   61    56,895    10.7   3.02 (1.97, 4.64) \*\*\*   2.48 (1.59, 3.87) \*\*\*
  Comorbidity ^§^                                                                                                 
  No                47                          26,518   17.7   65    211,891   3.07   5.77 (3.97, 8.40) \*\*\*   5.93 (4.07, 8.63) \*\*\*
  Yes               69                          22,240   31.0   60    31,895    18.8   1.65 (1.17, 2.33) \*\*     1.80 (1.25, 2.58) \*\*

PY, person years; Rate ^\#^, incidence rate per 10,000 person years. Crude HR ^†^, relative hazard ratio. Adjusted HR ^‡^, hazard ratio adjusted for age, sex, and comorbidities of diabetes, hypertension, hyperlipidemia, head injury, depression, stroke, cirrhosis, CAD, CHF, and AF. Comorbidity ^§^: Patients with any one of the comorbidities (including diabetes, hypertension, hyperlipidemia, head injury, depression, stroke, cirrhosis, CAD, CHF, and AF) were classified as the comorbidity group. \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.
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###### 

Cox proportional hazard regression analysis of the risk of seizures associated with the interactions of organophosphate poisoning and comorbidities.

  ---------------------------------------------------------------------------------------------------------
  Variables         Crude HR ^†^ (95% CI)   Adjusted HR ^‡^\           *p*-Value ^†^              
                                            (95% CI)                                              
  ----------------- ----------------------- -------------------------- -------------------------- ---------
  Organophosphate   Hypertension                                                                  \<0.001

  No                No                      1 (Reference)              1 (Reference)              

  No                Yes                     6.32 (4.30--9.30) \*\*\*   4.99 (3.32--7.50) \*\*\*   

  Yes               No                      5.40 (4.01--7.28) \*\*\*   5.54 (4.11--7.47) \*\*\*   

  Yes               Yes                     10.0 (6.65--15.1) \*\*\*   8.84 (5.81--13.4) \*\*\*   

  Organophosphate   Stroke                                                                        0.004

  No                No                      1 (Reference)              1 (Reference)              

  No                Yes                     9.28 (6.02--14.3) \*\*\*   7.19 (4.58--11.3) \*\*\*   

  Yes               No                      4.94 (3.72--6.54) \*\*\*   5.04 (3.80--6.68) \*\*\*   

  Yes               Yes                     17.7 (11.0--28.4) \*\*\*   15.1 (9.35--24.4) \*\*\*   

  Organophosphate   Head injury                                                                   0.007

  No                No                      1 (Reference)              1 (Reference)              

  No                Yes                     5.27 (3.07--9.03) \*\*\*   4.96 (2.89--8.51) \*\*\*   

  Yes               No                      4.69 (3.57--6.17) \*\*\*   4.80 (3.65--6.32) \*\*\*   

  Yes               Yes                     9.07 (5.63--14.6) \*\*\*   9.50 (5.89--15.3) \*\*\*   

  Organophosphate   Cirrhosis                                                                     0.96

  No                No                      1 (Reference)              1 (Reference)              

  No                Yes                     4.03 (2.04--7.94) \*\*\*   3.36 (1.70--6.63) \*\*\*   

  Yes               No                      4.09 (3.11--5.38) \*\*\*   4.19 (3.19--5.52) \*\*\*   

  Yes               Yes                     16.8 (10.9--25.9) \*\*\*   16.6 (10.8--25.6) \*\*\*   

  Organophosphate   CHF                                                                           0.02

  No                No                      1 (Reference)              1 (Reference)              

  No                Yes                     13.6 (6.87--26.8) \*\*\*   9.86 (4.94--19.7) \*\*\*   

  Yes               No                      4.80 (3.70--6.23) \*\*\*   4.92 (3.79--6.38) \*\*\*   

  Yes               Yes                     16.5 (6.72--40.3) \*\*\*   13.6 (5.53--33.5) \*\*\*   

  Organophosphate   AF                                                                            0.04

  No                No                      1 (Reference)              1 (Reference)              

  No                Yes                     12.9 (6.01--27.7) \*\*\*   9.01 (4.16--19.5) \*\*\*   

  Yes               No                      4.75 (3.67--6.15) \*\*\*   4.88 (3.76--6.32) \*\*\*   

  Yes               Yes                     16.7 (6.15--45.2) \*\*\*   13.1 (4.81--35.6) \*\*\*   
  ---------------------------------------------------------------------------------------------------------

Crude HR ^†^, relative hazard ratio; Adjusted HR ^‡^, hazard ratio adjusted for age and sex. \*\*\* *p* \< 0.001. ^†^ *p* for interaction.
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###### 

Trends of seizure event risk stratified by follow-up years.

  Variables   Organophosphate Poisoning                                                                    
  ----------- --------------------------- -------- ------ ---- --------- ------ -------------------------- --------------------------
  ≤1          32                          7521     42.6   18   35,870    5.02   8.39 (4.71--14.9) \*\*\*   7.71 (4.23--14.0) \*\*\*
  2--5        52                          23,939   21.7   51   118,635   4.30   5.05 (3.43--7.43) \*\*\*   3.71 (2.45--5.62) \*\*\*
  \>5         32                          17,298   18.5   56   89,280    6.27   2.95 (1.91--4.55) \*\*\*   2.13 (1.33--3.41) \*\*

PY, person years; Rate, incidence rate per 10,000 person years; Crude HR ^†^, relative hazard ratio; Adjusted HR ^‡^, hazard ratio adjusted for age, sex, and comorbidities of diabetes, hypertension, hyperlipidemia, head injury, depression, stroke, cirrhosis, CAD, CHF, and AF. \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.
